                               SEQUENCE LISTING

<110> ELUCIDA ONCOLOGY, INC.
 
<120> CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND 
      USES THEREOF

<130> 761825.290010

<140> PCT/US2021/056621
<141> 2021-10-26

<150> 63/254,837
<151> 2021-10-12

<150> 63/242,201
<151> 2021-09-09

<150> 63/222,181
<151> 2021-07-15

<150> 63/155,043
<151> 2021-03-01

<150> 63/117,110
<151> 2020-11-23

<150> 63/116,393
<151> 2020-11-20

<150> 63/105,995
<151> 2020-10-27

<160> 15    

<170> PatentIn version 3.5

<210> 1
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 1
Val Lys 
1       


<210> 2
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> Citrulline

<400> 2
Val Xaa 
1       


<210> 3
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
Phe Lys 
1       


<210> 4
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
Trp Lys 
1       


<210> 5
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 5
Asp Lys 
1       


<210> 6
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 6
Val Arg 
1       


<210> 7
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Val Ala 
1       


<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> Sarcosine

<400> 8
Val Phe Gly Xaa 
1               


<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> Citrulline

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Sarcosine

<400> 9
Val Xaa Gly Xaa 
1               


<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> Sarcosine

<400> 10
Val Lys Gly Xaa 
1               


<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> Sarcosine

<400> 11
Val Ala Gly Xaa 
1               


<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 12
Val Phe Gly Pro 
1               


<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> Citrulline

<400> 13
Val Xaa Gly Pro 
1               


<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 14
Val Lys Gly Pro 
1               


<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 15
Val Ala Gly Pro 
1               


